Exon 20 Group, a multistakeholder organization
@Exon20Group
Followers
2K
Following
2K
Media
11
Statuses
2K
Global org: patients/carers, HCPs, pharma, labs, scientists, working to cure #NSCLC #HER2 & #EGFR #Exon20 insertions (in 25 cancers +) [email protected]
83 countries served
Joined July 2017
@JennyCarlisleMD @TumorBoardTues @LealTiciana @FordePatrick @DrMarkAwad @JulieBrahmer @TonyMok9 @RamalingamMD @RachelSanbornMD @KarenReckampMD @AnaVManana @DevikaDasMD @JSabari @CharuAggarwalMD @tehfem @ElizSMcKenna @JineshGheeya @ShrutiPatelMD @NarjustFlorezMD @HosseinBorghaei @ThanksCancer @IASLC @IbiayiMD @NCCN @JohnEbbenMDPhD @oncoOuLungCA @drkpavithran @DrSteveMartin @khushmanmd @RenoHemonc @VivekSubbiah @StephenVLiu @juanosoriomd @n8pennell @LeciaSequist @NicoleKuderer @bensolomon1 @DavidOReilly2 @US_FDA @Latinamd @ShaalanBeg @msalmanfaisal @ADesaiMD @_Vila_L @FawziAbuRous @DrZ_84 @idamicaily @ASCO Don’t let your #EGFR #Exon20 and #HER2 #Exon20 patients miss out on the wonderful, caring community of patients and care partners (+ family members) in the multi-stakeholder @Exon20Group We have peer-to-peer counseling through our Angel Buddies program, oncology nursing services,
1
3
23
@JuliaRotow gives a comprehensive review of the evolving space of “HER2 mutation and overexpression in NSCLC” offering very helpful insights in managing this disease @Exon20Group #NSCLC #LCSM #Oncology
0
2
6
🫁 New in Nature Review Clinical Oncology: mapping EGFR-TKI resistance in EGFR-mutant NSCLC https://t.co/qzZxRxVcz7 ▪️ Resistance is inevitable (on-target, bypass, or lineage transformation) ▪️ Shift toward ctDNA-based early monitoring ▪️ Next moves? 4th-gen EGFR TKIs, EGFR–MET
nature.com
Nature Reviews Clinical Oncology - Third-generation EGFR tyrosine kinase inhibitors such as osimertinib have substantially improved clinical outcomes in advanced-stage EGFR-mutant non-small-cell...
2
36
99
This is the most forward looking approach the FDA has taken with the expansion of scientific knowledge today. Well done @VPrasadMDMPH @DrMakaryFDA. I love these statements: "An appropriately designed study with a small sample size can support licensure of a product for which
59
258
1K
A decade of progress in #lungcancer treatment shows what’s possible when research, innovation & patient care come together. Dr @tnewsomdavis finds hope in the next wave of targeted & immunotherapies - for more time, more moments, more possibility. #StoriesOfLungCancer #LCAM25
1
8
17
European oncologists saw the light that ALC matters. Only 4.6% of patients with lymphocyte counts under 1,000 were alive 4 years after surgery compared to 23% with lymphocyte counts above 1,000. The lightbulb that survival depends on your NK cells has to be turned on in the USA.
42
161
679
Antibody–drug conjugates in combination therapy: defining the next chapter☆ - Annals of Oncology https://t.co/2wSBonrMd4
@Annals_Oncology @myESMO @tompowles1 @OncoAlert
0
23
52
For readers interested in bispecific antibodies as cancer therapies, here's a review https://t.co/9xKq65uYhP
https://t.co/ybCSH295GO
1
54
152
Are germline variants (GPVs) risk factors for early-onset lung cancer? @JTOonline - GPVs identified in 350 early (<40yr) & 1441 late-onset (≥41yr) cases - GPVs in p53, BRCA1, BRCA2, ALKBH2 (DNA repair gene) = ⬆️ lung adeno risk @OncoAlert #LCSM
https://t.co/CdUbSL6yY3
jto.org
Up to 54% of all lung adenocarcinoma (LADC) cases in Asian populations occur in never-smoking women, suggesting that the impact of smoking and other environmental factors on the risk of early-onset...
2
18
51
Congratulations to HERNEXEOS/zongertinib for being in the second batch of FDA National Priority Voucher announcements! This is great news for NSCLC HER2 exon 20/HER2 lung cancer patients.
fda.gov
The U.S. Food and Drug Administration today announced six additional awardees under the Commissioner’s National Priority Voucher (CNPV) pilot program.
0
0
3
Sing it!! Absolutely correct! More NGS testing is imperative.
How reliable is PCR in detecting all EGFR mutations? At ILCS 2025, @TommyJohn00 showed striking differences in EGFR mutation prevalence between Asian and Western populations and highlighted the high missed detection rate of exon 20 insertions with PCR. With over 100 EGFR
0
0
4
We’re proud to partner with @cure_today for the Educated Patient® Lung Cancer Summit! Join us Nov 15 at Convene – 75 Rockefeller Plaza, NYC, to connect, learn, and empower the #lungcancer community. Learn more & register: https://t.co/9V23bbejBd
registration.curetoday.com
The CURE Educated Patient® Lung Cancer Summit is a half-day, in-person educational program designed to empower, inform, and connect people living with lung cancer, their caregivers, and advocates....
0
0
3
Working to explain to the world how and why Bioshield works. T cells and NK cells kill cancer, that’s irrefutable. Low NK cells and T cells means cancer grows, that’s irrefutable. So if there is a drug available to boost NK and T cells then there is better chance to kill
189
773
3K
Thank you, Susie, so much for your support!!
My current treatment is the only one available in the UK for Exon 20 and is only available privately but with the hard work of the @Exon20Group there are more treatments being trialled all the time and with that comes a whole lot of hope 😊 2/2
0
0
5
Absolutely right!
Basically agree with this list. Would also add promising data for EGFR and HER2 exon 20 TKIs as big wins in 2025. @lcsmchat @OncoAlert @OncogeneCancer @Exon20Group
0
0
3
Updated data on combination options seen at #ESMO25 for metastatic non-small cell lung cancer w/ EGFR mutated disease. Stuck w/ cross trial comparisons for now! We touched on this data and our options 👇👇 with @lungoncdoc! @EGFRSummit #OncTwitter #lcsm @OncoAlert @OncUpdates
In our “Challenging Cases” discussion on metastatic NSCLC mEGFR w/ @lungoncdoc we touch on: ✅ Rx options ✅ AE management ✅ Sequencing Full discussion: ⭐️ https://t.co/XFMkB6kxmY ⭐️ Also on the “Oncology Brothers” podcast #OncTwitter @OncUpdates
2
32
79
Thank you so much for sharing your thoughts/experience and your work around this @jillfeldman4! I am myself guilty of focusing on COCOON & SKIPIRR “just” as “AE management” rather than also appreciating the ⬆️ in QoL! With Ami-Laz, I always use this slide as a reference!
Fantastic, thoughtful discussion between @OncBrothers & @lungoncdoc about 1st line treatment options for #EGFR #NSCLC. Having options that have significant OS benefits is amazing, but all regimens have toxicities. Every lung #onc should not just prescribe treatment, but also
1
18
62
🆕 Scientists @unimelb say preserving lymph nodes during cancer surgery could improve how people respond to immunotherapy. Lymph nodes help train & sustain cancer-fighting T cells, but they’re also common sites of metastasis in #LungCancer, so surgery must balance both roles.
0
4
17
The quantity and quality of information derived from ESMO in thoracic oncology reflects the association's importance to global academic growth in cancer. Congratulations on the transformation of ESMO; it is a great reflection and guide for Latin America.
1
4
26
If you missed our session on innovative approaches in NSCLC covering ADC, bsAB, PROTACs/protein degraders, MTAP deletions I encourage you to watch the recording. My wonderful co-char @mayluciemeyer and expert faculty @FedericoCappuz1, Prof Keith Kerr and Prof Nicolas Thoma
1
2
10